Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain

  • End date
    Dec 28, 2022
  • participants needed
  • sponsor
    Stayble Therapeutics
Updated on 28 January 2021


This is a phase IIb, prospective, multi-country, multicenter, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and transformation of NP following single intradiscal injection of STA363 (lactic acid) into one or two IVDs compared to placebo for the treatment of discogenic low back pain. This study will be conducted in Russia, Spain and the Netherlands.


This is a phase IIb, prospective, multi-country, multicenter, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy, safety and transformation of NP following single intradiscal injection of STA363 (lactic acid) into one or two IVDs compared to placebo for the treatment of discogenic low back pain. This study will be conducted in Russia, Spain and the Netherlands.

The primary objective is to demonstrate superiority of STA363 over placebo in reducing low back pain as measured by the NRS. A total of 168 patients will be screened in the study with the aim to recruit 126 patients to be randomly allocated to one of the three treatment


Group 1 - 42 patients will receive STA363 containing 90 mg (60 mg/mL) lactic acid Group 2 - 42 patients will receive STA363 containing 180 mg (120 mg/mL) lactic acid Group 3 - 42 patients will receive placebo

The investigational medical product (IMP) will be injected into the center of up to two IVDs. Patients with two discs appropriate for treatment will be treated at both affected levels by two separate injections.

Each patient will have 5 visits to study site and 1 telephone call. The patient's total time in the study will be approximately 61 weeks (~15 months) including an 8-week screening period.

Each patient will perform a screening visit (Visit 1) maximum 60 days before planned treatment. Randomization and treatment will be performed at Visit 2 (Day 1) after confirmation of patient's eligibility for the study. The IMP will be administered, monitored by fluoroscopy or other available method of real-time x-ray imaging to ensure that an injection is correctly placed in the IVD nucleus and that no leakage occurs. Immediately after treatment the patients should remain supine for as long as possible (at least 1 hour). For safety reasons, patients will be allowed to leave the clinic not earlier than 2 hours after the last injection. After leaving the clinic, patients will be offered analgesics and/or other measures according to standard clinical practice. They will also be given advice on restricted physical activity during the first two weeks after injection. Patients should not drive or operate machinery for 12 hours following the treatment procedure.

Patients will be followed up at 1 month (Visit 3/Day 307, visit to study site), 3 months (Visit 4/Day 907, telephone call), 6 months (Visit 5/Day 1807, visit to study site) and 12 months (Visit 6/Day 3607, visit to study site) after treatment. Follow-up MRI will be conducted as part of Visit 5 and Visit 6, to assess the transformation of the NP into connective tissue and other disc characteristics.

Condition Discogenic Pain
Treatment Placebo, STA363 containing 90 mg (60 mg/mL) lactic acid, STA363 containing 180 mg (120 mg/mL) lactic acid
Clinical Study IdentifierNCT04673461
SponsorStayble Therapeutics
Last Modified on28 January 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent prior to any study related procedures
Male and female patients 18 and 70 years
Chronic discogenic low back pain present for more than 6 months prior to the screening visit
Insufficient response or lack of response to at least 6 months of non-operative treatment (analgesics and/or anti-inflammatory medications [paracetamol, non-steroidal anti-inflammatory agents (NSAIDs), opioids], physiotherapy, rehabilitation therapy etc.)
Patients who meet all the following NRS selection criteria
Presence of 5 pain NRS assessments (entries) for 7 consecutive days
NRS daily pain scores between 3-9
Not more than two ratings "3
One or two treatable IVDs of Pfirrmann grade 2 to 3 on MRI at L2/3 to L5/S1 as confirmed by a central reader, AND the following criteria are met
Treatable IVD(s) must be IVD(s) with the highest Pfirrmann grade observed in the patient (e.g. a patient with one IVD of grade 3 and four IVDs of grade 2 is considered eligible only if IVD of grade 3 will be injected)
Patients with treatable IVD(s) of grade 2 must have all other lumbar discs rated as grade 1
Not more than two IVDs of grade 3 at any lumbar level
No IVDs of grade 4 or 5 at any lumbar level
Ability to understand the written and verbal information about the study

Exclusion Criteria

Treatment with any investigational product within 3 months prior to the screening visit
Patients with more than two painful IVDs
A painful IVD above L2/3 level
Current infection or prior history of spinal infection (e.g., discitis, septic arthritis, epidural abscess) or an active systemic infection
Previous lumbar spine surgery
Previous disc invasive treatment procedures at the affected level(s) (e.g., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation)
Evidence of prior lumbar vertebral body fracture or trauma
Need for spinal decompression assessed by the Investigator
Presence of IVD extrusion or sequestration, or other radiologic findings that in the opinion of the investigator disqualify the patient from being included
Spondylolisthesis or retrolisthesis Grade 2 and above or spondylolysis at the index or adjacent level(s)
Lumbar spondylitis or other undifferentiated spondyloarthropathy affecting the index IVD
Patients previously included in the study
Patients suffering from psychosomatic pain in the opinion of the Investigator
Leg pain of compressive origin
Patients requiring continuous treatment with warfarin or other anticoagulant therapy
History of significant neurologic or psychiatric disorders including dementia or seizures
Known alcohol and/or drug abuse
Severe intercurrent illness (e.g. rheumatic disease or chronic pain syndrome) or concomitant treatment (e.g. immunosuppressive drugs), which, in the opinion of the Investigator, may put the patient at risk when participating in the study, or affect the patient's ability to take part in the study
Pregnant or lactating females, or intention to become pregnant within the study period
Known allergy to any of the components of the drug product or placebo
Known allergy or intolerance to the contrast agent Omnipaque
Known opioid allergy or intolerance
Any other condition that, in the opinion of the Investigator, precludes the patient from taking part in this study
Any specific contraindication for MRI such as claustrophobia, intracranial clips or pacemakers
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note